Bladder Cancer Imaging Drug Side Effects & Dosage

0
17


Generic drug: hexaminolevulinate hydrochloride

Brand name: Cysview

What is Cysview (hexaminolevulinate hydrochloride), and how does it work?

Cysview (hexaminolevulinate hydrochloride) is an imaging drug used in the cystoscopic detection of non-muscle invasive papillary cancer of the bladder among patients suspected or known to have lesion(s) on the basis of a prior cystoscopy. Cysview is used with the Karl Storz D-Light C Photodynamic Diagnostic (PDD) system to perform cystoscopy with the blue light setting (Mode 2) as an adjunct to the white light setting (Mode 1).

What are the side effects of Cysview?

Common side effects of Cysview include:

For bladder instillation only

What drugs interact with Cysview?

No specific drug interaction studies have been performed.

Is Cysview safe to use while pregnant or breastfeeding?

  • There are no available data on Cysview use in pregnant women to inform a drug associated risk of adverse developmental outcomes.
  • Adequate reproductive and developmental toxicity studies in animals have not been performed. Systemic absorption following administration of Cysview is expected to be minimal.
  • There are no data on the presence of hexaminolevulinate in human or animal milk, the effects on a breastfed infant, or the effects on milk production. Systemic absorption following administration of Cysview is expected to be minimal.
  • The lack of clinical data during lactation precludes a clear determination of the risk of Cysview to an infant during lactation; therefore, the development and health benefits of breastfeeding should be considered along with the mother’s clinical need for Cysview and any potential adverse effects on the breastfed infant from Cysview or from the underlying maternal condition.




SLIDESHOW


Prostate Cancer Symptoms, PSA Test, Treatments
See Slideshow

Medically Reviewed on 3/31/2021

References


All sections courtesy of the U.S. Food and Drug Administration



Source link

Share and Enjoy !

0Shares
0 0

NO COMMENTS